Given that SGK1 expression is required for androgen-dependent growth of prostate cancer cells, Sherk et al. (49) developed a novel heterocyclic indazole derivate, GSK650394, which is the first reported SGK1 inhibitor that restrains the enzymatic activity of SGK1, with half maximal inhibitory concentration (IC50) values of 62 nM based on an in vitro scintillation proximity assay (SPA). Here, SGK1 is linked to prostate carcinoma.